FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385564669> ?p ?o ?g. }

• W4385564669 endingPage "1066" @default.
• W4385564669 startingPage "1057" @default.
• W4385564669 abstract "This real-world study evaluated the impact of dapagliflozin on short-term medical costs in patients with stage 3 chronic kidney disease (CKD).This retrospective, observational cohort study used medical and pharmacy claims data from IQVIA PharMetrics Plus. Patients aged ≥18 years with a filled dapagliflozin prescription after stage 3 CKD diagnosis between September 2020 and December 2021 were 1:1 propensity score matched with patients with stage 3 CKD who did not receive dapagliflozin. The primary endpoint was cardiorenal medical costs to payers over 6 months; all-cause medical and pharmacy costs were also analyzed. Within the overall population, there was a new-user subgroup of patients with no sodium-glucose co-transporter-2 use during baseline.The new-user subgroup included 503 matched patients per cohort. Mean per-patient cardiorenal medical costs were reduced by 49.0% in the dapagliflozin versus non-dapagliflozin cohort ($3172.15 vs $6219.50; P < 0.001). Mean all-cause medical costs were reduced ($8043.58 vs $12,194.87; P < 0.001) and mean all-cause pharmacy costs were increased ($9056.98 vs $7453.23; P = 0.22). Results were similar for the overall population.This study showed dapagliflozin was associated with reduced cardiorenal medical costs over 6 months compared with no dapagliflozin treatment in patients with stage 3 CKD, demonstrating real-world medical cost savings.Chronic kidney disease (CKD) is a condition in which the kidneys become progressively less effective at filtering blood. Patients with CKD also have an increased risk of cardiovascular disease, high blood pressure, and stroke. Dapagliflozin is a drug that can be prescribed for adults with CKD to reduce the risk of CKD worsening, hospitalization for heart failure, and death from cardiovascular disease. Because the cost of medications could affect whether they are prescribed to patients who could benefit from them, our goal was to study the impact of dapagliflozin treatment on short-term costs for patients in the United States with CKD. We used health insurance claims data to compare medical costs (sum of costs for treatment during hospital admissions and outpatient and emergency department visits) and pharmacy costs over 6 months between patients with stage 3 CKD treated with dapagliflozin with those for a matching group of patients who were not treated with dapagliflozin. The dapagliflozin group had a lower average medical cost for cardiorenal causes (related to CKD, including hospitalization for heart failure) paid by health insurance than the non-dapagliflozin group; the average cardiorenal medical cost patients paid themselves (out-of-pocket) was also lower for the dapagliflozin group. The average medical cost for all causes paid by insurance was also lower for the dapagliflozin group; this reduction was larger than the increase in the average all-cause pharmacy cost in the dapagliflozin group. Our study showed that treatment with dapagliflozin can lead to medical cost savings for patients with CKD." @default.
• W4385564669 created "2023-08-05" @default.
• W4385564669 creator A5006801478 @default.
• W4385564669 creator A5067426250 @default.
• W4385564669 creator A5078675744 @default.
• W4385564669 creator A5088408688 @default.
• W4385564669 date "2023-08-04" @default.
• W4385564669 modified "2023-10-17" @default.
• W4385564669 title "Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study" @default.
• W4385564669 cites W2146264128 @default.
• W4385564669 cites W2235148537 @default.
• W4385564669 cites W2418869077 @default.
• W4385564669 cites W2424539745 @default.
• W4385564669 cites W2626446274 @default.
• W4385564669 cites W2900413769 @default.
• W4385564669 cites W2939222610 @default.
• W4385564669 cites W2947866926 @default.
• W4385564669 cites W2949665037 @default.
• W4385564669 cites W2973242786 @default.
• W4385564669 cites W2974260792 @default.
• W4385564669 cites W3081830235 @default.
• W4385564669 cites W3088173406 @default.
• W4385564669 cites W3092582090 @default.
• W4385564669 cites W3193297191 @default.
• W4385564669 cites W3201867211 @default.
• W4385564669 cites W4200513993 @default.
• W4385564669 cites W4210858922 @default.
• W4385564669 cites W4220734654 @default.
• W4385564669 cites W4293354639 @default.
• W4385564669 cites W4300688387 @default.
• W4385564669 cites W4300689929 @default.
• W4385564669 cites W4306783667 @default.
• W4385564669 cites W4308060342 @default.
• W4385564669 cites W4308183941 @default.
• W4385564669 cites W4311264009 @default.
• W4385564669 doi "https://doi.org/10.1080/14737167.2023.2237679" @default.
• W4385564669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37540162" @default.
• W4385564669 hasPublicationYear "2023" @default.
• W4385564669 type Work @default.
• W4385564669 citedByCount "1" @default.
• W4385564669 crossrefType "journal-article" @default.
• W4385564669 hasAuthorship W4385564669A5006801478 @default.
• W4385564669 hasAuthorship W4385564669A5067426250 @default.
• W4385564669 hasAuthorship W4385564669A5078675744 @default.
• W4385564669 hasAuthorship W4385564669A5088408688 @default.
• W4385564669 hasBestOaLocation W43855646691 @default.
• W4385564669 hasConcept C104863432 @default.
• W4385564669 hasConcept C126322002 @default.
• W4385564669 hasConcept C134018914 @default.
• W4385564669 hasConcept C159641895 @default.
• W4385564669 hasConcept C167135981 @default.
• W4385564669 hasConcept C177713679 @default.
• W4385564669 hasConcept C201903717 @default.
• W4385564669 hasConcept C2777180221 @default.
• W4385564669 hasConcept C2777422806 @default.
• W4385564669 hasConcept C2778653478 @default.
• W4385564669 hasConcept C2908647359 @default.
• W4385564669 hasConcept C512399662 @default.
• W4385564669 hasConcept C555293320 @default.
• W4385564669 hasConcept C71924100 @default.
• W4385564669 hasConcept C72563966 @default.
• W4385564669 hasConcept C99454951 @default.
• W4385564669 hasConceptScore W4385564669C104863432 @default.
• W4385564669 hasConceptScore W4385564669C126322002 @default.
• W4385564669 hasConceptScore W4385564669C134018914 @default.
• W4385564669 hasConceptScore W4385564669C159641895 @default.
• W4385564669 hasConceptScore W4385564669C167135981 @default.
• W4385564669 hasConceptScore W4385564669C177713679 @default.
• W4385564669 hasConceptScore W4385564669C201903717 @default.
• W4385564669 hasConceptScore W4385564669C2777180221 @default.
• W4385564669 hasConceptScore W4385564669C2777422806 @default.
• W4385564669 hasConceptScore W4385564669C2778653478 @default.
• W4385564669 hasConceptScore W4385564669C2908647359 @default.
• W4385564669 hasConceptScore W4385564669C512399662 @default.
• W4385564669 hasConceptScore W4385564669C555293320 @default.
• W4385564669 hasConceptScore W4385564669C71924100 @default.
• W4385564669 hasConceptScore W4385564669C72563966 @default.
• W4385564669 hasConceptScore W4385564669C99454951 @default.
• W4385564669 hasFunder F4320307770 @default.
• W4385564669 hasIssue "9" @default.
• W4385564669 hasLocation W43855646691 @default.
• W4385564669 hasLocation W43855646692 @default.
• W4385564669 hasLocation W43855646693 @default.
• W4385564669 hasOpenAccess W4385564669 @default.
• W4385564669 hasPrimaryLocation W43855646691 @default.
• W4385564669 hasRelatedWork W102536597 @default.
• W4385564669 hasRelatedWork W1506615841 @default.
• W4385564669 hasRelatedWork W1971368128 @default.
• W4385564669 hasRelatedWork W2338997164 @default.
• W4385564669 hasRelatedWork W2549923796 @default.
• W4385564669 hasRelatedWork W2790532628 @default.
• W4385564669 hasRelatedWork W3205964248 @default.
• W4385564669 hasRelatedWork W4200133826 @default.
• W4385564669 hasRelatedWork W4213008657 @default.
• W4385564669 hasRelatedWork W4320929188 @default.
• W4385564669 hasVolume "23" @default.
• W4385564669 isParatext "false" @default.
• W4385564669 isRetracted "false" @default.

• next